Safety and antiviral activity of combination HIV-1 broadly neutralizing antibodies in viremic individuals (Q59351843)

30

Gerd Fätkenheuer

0 references

Michel C. Nussenzweig

33

Michel C Nussenzweig

0 references

Georgia D. Tomaras

28

Georgia D Tomaras

0 references

Nicole Yates

24

Nicole L Yates

0 references

author name string

Yotam Bar-On

1

0 references

Henning Gruell

2

0 references

Till Schoofs

3

0 references

Joy A Pai

4

0 references

Lilian Nogueira

5

0 references

Allison L Butler

6

0 references

Katrina Millard

7

0 references

Clara Lehmann

8

0 references

Isabelle Suárez

9

0 references

Thiago Y Oliveira

10

0 references

Theodora Karagounis

11

0 references

Christoph Wyen

13

0 references

Stefan Scholten

14

0 references

Lisa Handl

15

0 references

Shiraz Belblidia

16

0 references

Juan P Dizon

17

0 references

Jörg J Vehreschild

18

0 references

Maggi Witmer-Pack

19

0 references

Irina Shimeliovich

20

0 references

Kanika Jain

21

0 references

Kerstin Fiddike

22

0 references

Kelly E Seaton

23

0 references

Jill Horowitz

25

0 references

Roy M Gulick

26

0 references

Nico Pfeifer

27

0 references

Michael S Seaman

29

0 references

Marina Caskey

31

0 references

Florian Klein

https://api.crossref.org/works/10.1038%2FS41591-018-0186-4

32

0 references

language of work or name

English

0 references

publication date

November 2018

0 references

published in

Nature Medicine

0 references

volume

24

0 references

issue

11

0 references

page(s)

1701-1707

0 references

1 reference

7 January 2021

Mechanisms of HIV-1 escape from immune responses and antiretroviral drugs

1 reference

https://api.crossref.org/works/10.1038%2FS41591-018-0186-4

7 January 2021

Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4+ T cells.

1 reference

https://api.crossref.org/works/10.1038%2FS41591-018-0186-4

7 January 2021

Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy

1 reference

https://api.crossref.org/works/10.1038%2FS41591-018-0186-4

7 January 2021

Passive immunotherapy of viral infections: 'super-antibodies' enter the fray

1 reference

https://api.crossref.org/works/10.1038%2FS41591-018-0186-4

7 January 2021

Antibodies in HIV-1 vaccine development and therapy

1 reference

https://api.crossref.org/works/10.1038%2FS41591-018-0186-4

7 January 2021

Viraemia suppressed in HIV-1-infected humans by broadly neutralizing antibody 3BNC117.

1 reference

https://api.crossref.org/works/10.1038%2FS41591-018-0186-4

7 January 2021

Antibody 10-1074 suppresses viremia in HIV-1-infected individuals

1 reference

https://api.crossref.org/works/10.1038%2FS41591-018-0186-4

7 January 2021

Virologic effects of broadly neutralizing antibody VRC01 administration during chronic HIV-1 infection

1 reference

https://api.crossref.org/works/10.1038%2FS41591-018-0186-4

7 January 2021

Passive immunization with the anti-HIV-1 human monoclonal antibody (hMAb) 4E10 and the hMAb combination 4E10/2F5/2G12

1 reference

https://api.crossref.org/works/10.1038%2FS41591-018-0186-4

7 January 2021

Adjunctive passive immunotherapy in human immunodeficiency virus type 1-infected individuals treated with antiviral therapy during acute and early infection

1 reference

https://api.crossref.org/works/10.1038%2FS41591-018-0186-4

7 January 2021

Delay of HIV-1 rebound after cessation of antiretroviral therapy through passive transfer of human neutralizing antibodies

1 reference

https://api.crossref.org/works/10.1038%2FS41591-018-0186-4

7 January 2021

Sequence and Structural Convergence of Broad and Potent HIV Antibodies That Mimic CD4 Binding

1 reference

https://api.crossref.org/works/10.1038%2FS41591-018-0186-4

7 January 2021

Complex-type N-glycan recognition by potent broadly neutralizing HIV antibodies

1 reference

https://api.crossref.org/works/10.1038%2FS41591-018-0186-4

7 January 2021

Combination therapy with anti-HIV-1 antibodies maintains viral suppression

1 reference

https://api.crossref.org/works/10.1038%2FS41591-018-0186-4

7 January 2021

Optimization and validation of the TZM-bl assay for standardized assessments of neutralizing antibodies against HIV-1.

1 reference

https://api.crossref.org/works/10.1038%2FS41591-018-0186-4

7 January 2021

HIV-1 antibody 3BNC117 suppresses viral rebound in humans during treatment interruption

1 reference

https://api.crossref.org/works/10.1038%2FS41591-018-0186-4

7 January 2021

Clinical pharmacokinetics of therapeutic monoclonal antibodies

1 reference

https://api.crossref.org/works/10.1038%2FS41591-018-0186-4

7 January 2021

HIV-1 suppression and durable control by combining single broadly neutralizing antibodies and antiretroviral drugs in humanized mice

1 reference

https://api.crossref.org/works/10.1038%2FS41591-018-0186-4

7 January 2021

HIV therapy by a combination of broadly neutralizing antibodies in humanized mice.

1 reference

https://api.crossref.org/works/10.1038%2FS41591-018-0186-4

7 January 2021

Enhanced HIV-1 immunotherapy by commonly arising antibodies that target virus escape variants

1 reference

https://api.crossref.org/works/10.1038%2FS41591-018-0186-4

7 January 2021

Antibody-mediated immunotherapy of macaques chronically infected with SHIV suppresses viraemia

1 reference

https://api.crossref.org/works/10.1038%2FS41591-018-0186-4

7 January 2021

Early antibody therapy can induce long-lasting immunity to SHIV

1 reference

https://api.crossref.org/works/10.1038%2FS41591-018-0186-4

7 January 2021

Unravelling the mechanisms of durable control of HIV-1.

1 reference

https://api.crossref.org/works/10.1038%2FS41591-018-0186-4

7 January 2021

HIV-1 fitness cost associated with escape from the VRC01 class of CD4 binding site neutralizing antibodies

1 reference

https://api.crossref.org/works/10.1038%2FS41591-018-0186-4

7 January 2021

Restricting HIV-1 pathways for escape using rationally designed anti–HIV-1 antibodies

1 reference

https://api.crossref.org/works/10.1038%2FS41591-018-0186-4

7 January 2021

Safety and pharmacokinetics of the Fc-modified HIV-1 human monoclonal antibody VRC01LS: A Phase 1 open-label clinical trial in healthy adults.

1 reference

https://api.crossref.org/works/10.1038%2FS41591-018-0186-4

7 January 2021

Enhanced neonatal Fc receptor function improves protection against primate SHIV infection

1 reference

https://api.crossref.org/works/10.1038%2FS41591-018-0186-4

7 January 2021

A novel investigational Fc-modified humanized monoclonal antibody, motavizumab-YTE, has an extended half-life in healthy adults

1 reference

https://api.crossref.org/works/10.1038%2FS41591-018-0186-4

7 January 2021

A single injection of crystallizable fragment domain-modified antibodies elicits durable protection from SHIV infection.

1 reference

https://api.crossref.org/works/10.1038%2FS41591-018-0186-4

7 January 2021

Multidonor Analysis Reveals Structural Elements, Genetic Determinants, and Maturation Pathway for HIV-1 Neutralization by VRC01-Class Antibodies

1 reference

https://api.crossref.org/works/10.1038%2FS41591-018-0186-4

7 January 2021

HIV-1 therapy with monoclonal antibody 3BNC117 elicits host immune responses against HIV-1.

1 reference

https://api.crossref.org/works/10.1038%2FS41591-018-0186-4

7 January 2021

Clustal W and Clustal X version 2.0

1 reference

https://api.crossref.org/works/10.1038%2FS41591-018-0186-4

7 January 2021

Longitudinal Antigenic Sequences and Sites from Intra-Host Evolution (LASSIE) Identifies Immune-Selected HIV Variants

1 reference

https://api.crossref.org/works/10.1038%2FS41591-018-0186-4

7 January 2021

New algorithms and methods to estimate maximum-likelihood phylogenies: assessing the performance of PhyML 3.0

1 reference

https://api.crossref.org/works/10.1038%2FS41591-018-0186-4

7 January 2021

RAxML version 8: a tool for phylogenetic analysis and post-analysis of large phylogenies

1 reference

https://api.crossref.org/works/10.1038%2FS41591-018-0186-4

7 January 2021

MAFFT Multiple Sequence Alignment Software Version 7: Improvements in Performance and Usability

1 reference

https://api.crossref.org/works/10.1038%2FS41591-018-0186-4

7 January 2021

High throughput functional analysis of HIV-1 env genes without cloning

1 reference

https://api.crossref.org/works/10.1038%2FS41591-018-0186-4

7 January 2021

Neutralizing activity of broadly neutralizing anti-HIV-1 antibodies against clade B clinical isolates produced in peripheral blood mononuclear cells

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/30258217

12 December 2020